Two Cases of Epidermal Growth Factor Receptor <scp>L861R</scp> Mutation‐Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib
Here, we present the first case showing the anti-tumor efficacy of afatinib and the second case showing the anti-tumor efficacy of osimertinib in a patient with EGFR L861R-positive lung adenocarcinoma. Despite their short treatment durations, afatinib and osimertinib may have potential clinical activity in patients with EGFR L861R-positive lung cancer.
Authors
- Hiroko Iwamoto (ORCID: https://orcid.org/0000-0002-0516-4341)
- Taku Nakashima (ORCID: https://orcid.org/0000-0002-0035-674X)
- Noboru Hattori (ORCID: https://orcid.org/0000-0002-8234-942X)
- Kakuhiro Yamaguchi (ORCID: https://orcid.org/0000-0002-9117-1934)
- Kiyofumi Shimoji (ORCID: https://orcid.org/0000-0001-5382-4730)
- Shinjiro Sakamoto (ORCID: https://orcid.org/0009-0009-3543-0813)
- Takeshi Masuda (ORCID: https://orcid.org/0000-0003-3557-0049)
- Kenzo Kagawa (ORCID: https://orcid.org/0009-0006-9910-0109)
- Yasushi Horimasu (ORCID: https://orcid.org/0000-0002-3390-8491)
- Hironobu Hamada (ORCID: https://orcid.org/0000-0002-7979-0708)
Institutions
- Hiroshima University (JP)
- Hiroshima University of Economics (JP)
- Hiroshima University Hospital (JP)
- Chugoku Rosai Hospital (JP)
Publication Details
- Journal
- Cancer Reports
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/cnr2.70420
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52